International AS Registry: The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative

Part of the Current Clinical Urology book series (CCU)


In August 2014, the Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative. This global project aims to create the largest centralized prostate cancer active surveillance database to date, comprising the majority of the world’s organized active surveillance patient data. This database will be used to optimize the management of men diagnosed with low-risk prostate cancer and reduce the burden of overtreatment in men with truly low-risk disease. Milestones of the project include the development of worldwide uniform guidelines on active surveillance and a web-based platform with information and guidelines on AS. The Movember Foundation has utilized its global networks and unique position as a multinational, large-scale funder of prostate cancer, testicular cancer, and suicide prevention programs, to unite clinicians and researchers from around the globe. To date, the GAP3 initiative includes 30 partners in 15 countries across five Movember regions (Australasia, Europe, UK, Canada, USA). Additional funding has been allocated to sustain the database, with a special focus on the role of MRI and genomic testing for the future management of active surveillance. GAP3 is the largest effort of its type to integrate patient data from men with prostate cancer on active surveillance protocols and provides a legal and technical framework for future projects to safely share data. The GAP3 project will allow patients and clinicians to have greater confidence in the decision to either delay or proceed with active treatment based on analyses and clinical guidelines from global and up-to-date data. The project provides an important opportunity to improve the lives of men diagnosed with low-risk prostate cancer.


Prostate cancer Active surveillance Database Registry Clinical guidelines Movember Foundation Eligibility Follow-up Progression MRI 


  1. 1.
    Cooperberg MR. Long-term active surveillance for prostate cancer: answers and questions. J Clin Oncol. 2015;33(3):238–40.CrossRefPubMedGoogle Scholar
  2. 2.
    Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol. 2015;33(30):3379–85.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Draft clinical practice guidelines PSA testing and early management of test-detected prostate cancer. Sydney: Cancer Council Australia. [Version URL:, cited 2015 Jun 4]. Available from:
  5. 5.
    Reekhaye A, Madaan S (2016) Active Surveillance for Prostate Cancer. J Cancer Clin Trials 1:109. doi: 10.4172/jcct.1000109.
  6. 6.
    Loeb S. Re: long-term follow-up of a large active surveillance cohort of patients with prostate cancer. Eur Urol. 2015;68(5):906–7.CrossRefGoogle Scholar
  7. 7.
    Reese AC, Landis P, Han M, Epstein JI, Carter HB. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis. J Urol. 2013;190(6):2033–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Prostate Cancer: Movember Foundation; [cited 2016 Aug 2]. Available from:
  9. 9.
    The Movember Foundation’s Global Action Plan: Movember Foundation; [cited 2016 Aug 11]. Available from:
  10. 10.
    Global Action Plan 3 Global Prostate Cancer Active Surveillance Initiative: Movember Foundation; [cited 2016 Aug 11]. Available from:
  11. 11.
    Prostate Cancer Working Group and Ministry of Health. Guidance on using active surveillance to manage men with low-risk prostate cancer. Wellington: Ministry of Health; 2015.Google Scholar
  12. 12.
    Hulsen T, Obbink H, van der Linden W, de Jonge C, Nieboer D, Bruinsma SM, Roobol MJ, Bangma CH. 958 Integrating large datasets for the Movember Global Action Plan on active surveillance for low risk prostate cancer. European Urology Supplements. 2016;15(3):e958, with permission from Elsevier.CrossRefGoogle Scholar
  13. 13.
    RStudio Team. RStudio: integrated development for R. Boston: RStudio; 2015. URL Scholar
  14. 14.
    R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008. ISBN 3-900051-07-0, URL Scholar
  15. 15.
    Stallinga HA, ten Napel H, Jansen GJ, Geertzen JH, de Vries Robbe PF, Roodbol PF. Does language ambiguity in clinical practice justify the introduction of standard terminology? An integrative review. J Clin Nurs. 2015;24(3–4):344–52.CrossRefPubMedGoogle Scholar
  16. 16.
    Kleynen M, Braun SM, Bleijlevens MH, Lexis MA, Rasquin SM, Halfens J, et al. Using a Delphi technique to seek consensus regarding definitions, descriptions and classification of terms related to implicit and explicit forms of motor learning. PLoS One. 2014;9(6):e100227.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, et al. Expert consensus document: semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. Nat Rev Urol. 2017;14(5):312–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016;13(3):151–67.CrossRefPubMedGoogle Scholar
  19. 19.
    Kates M, Tosoian J, Trock B, Feng Z, Carter B, Partin A. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and PRIAS protocols. J Urol. 2014;191(4):e513.CrossRefGoogle Scholar
  20. 20.
    Ankerst DP, Xia J, Thompson IM Jr, Hoefler J, Newcomb LF, Brooks JD, et al. Precision medicine in active surveillance for prostate cancer: development of the canary-early detection research network active surveillance biopsy risk calculator. Eur Urol. 2015;68(6):1083–8.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sooriakumaran P, Srivastava A, Christos P, Grover S, Shevchuk M, Tewari A. Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer. Int Urol Nephrol. 2012;44(2):459–70.CrossRefPubMedGoogle Scholar
  22. 22.
    Coley RY, Zeger SL, Mamawala M, Pienta KJ, Carter HB. Prediction of the pathologic Gleason score to inform a personalized management program for prostate cancer. Eur Urol. 2017;72(1):135–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Rizopoulos D. Joint models for longitudinal and time-to-event data, with applications in R. Boca Raton: Chapman and Hall/CRC; 2012. [R code]CrossRefGoogle Scholar
  24. 24.
    Cancer Care Nova Scotia (CCNS). Guidelines for the management of prostate cancer. .2006. Accessed 24 Jan 2015.
  25. 25.
    The National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Prostate cancer. .2014. Accessed 14 Jan 2015.
  26. 26.
    The National Institute for Health and Clinical Excellence (NICE). Prostate cancer: diagnosis and treatment. 2014. Accessed 25 May 2015.
  27. 27.
    American Urological Association (AUA). Guideline for the management of clinically localized prostate cancer: 2007 update. 2007. Accessed 4 Feb 2015.
  28. 28.
    European Association of Urology (EAU). Guidelines on prostate cancer. 2016. Accessed 1 Aug 2016.
  29. 29.
    German Society of Urology (GSU). Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. 2014. Accessed Jan 18 2015.
  30. 30.
    Dutch Urological Association (DUA). Richtlijn prostaatcarcinoom. 2014. Accessed Jan 28 2015.
  31. 31.
    Belgian Healthcare Knowledge Centre (KCE). A national clinical practice guideline on the management of localised prostate cancer. 2013. Accessed 5 Mar 2015.
  32. 32.
    South East Scotland Cancer Network (SCAN). SCAN guideline for active surveillance (deferred radical treatment) of early, low-risk, prostate cancer. 2009. Accessed 5 Feb 2015.
  33. 33.
    Aragon Institute of Health Sciences (I+CS). Clinical practice guideline for prostate cancer treatment. .2008. Accessed 10 Feb 2015.
  34. 34.
    Alberta Health Services (AHS). Alberta health services clinical practice guideline: prostate cancer. .2013. Accessed 4 May 2015.
  35. 35.
    Singapore Ministry of Health (NCCS). Guidelines on management of prostate cancer. .2014. Accessed 4 May 2015.
  36. 36.
    Prostate Cancer Taskforce (PCT). Diagnosis and management of prostate cancer in New Zealand men: recommendations from the prostate cancer taskforce. .2012. Accessed 4 May 2015.
  37. 37.
    The Finnish Medical Society Duodecim (FCCG). Prostate cancer (Eturauhassyöpä). 2014. Accessed 4 May 2015.
  38. 38.
    Morash C, Tey R, Agbassi C, Klotz L, McGowan T, Srigley J, et al. and the Active Surveillance Guideline development Group. Active surveillance for the management of localized prostate cancer: guideline recommendations. Toronto (ON): Cancer Care Ontario; 2014 Dec 10. Program in Evidence-based Care Guideline No.: 17–9.
  39. 39.
    Bruinsma S, Zhang L, Bangma C, Roobol M, Steyerberg E, Nieboer D, et al. PD28-05 worldwide variation in determinants for inclusion and follow-up in active surveillance for low-risk prostate cancer: results of the Movember foundation’s global action plan prostate cancer active surveillance (gap3) initiative. J Urol. 2009;197(4):e519.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of UrologyErasmus Medical CenterRotterdamThe Netherlands
  2. 2.Department of Public HealthErasmus MCRotterdamThe Netherlands
  3. 3.Department of Professional Health Solutions & ServicesPhilips ResearchEindhovenThe Netherlands
  4. 4.University of TorontoSunnybrook Health Sciences CentreTorontoCanada
  5. 5.Movember FoundationRichmondAustralia

Personalised recommendations